Please complete the CAPTCHA to continue
@januarytx.com
✓
2 phones found area 858
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Robin Jackman is listed as Founder and CEO, Venquis Therapeutics at Venquis Therapeutics, based in San Diego, California, United States. AeroLeads shows a work email signal at januarytx.com, phone signal with area code 858, and a matched LinkedIn profile for Robin Jackman.
Robin Jackman previously worked as Founder and CEO at Venquis Therapeutics and President at Blue Tungsten Llc. Robin Jackman holds Ph.D., Immunology from Harvard University.
This section adds company-level context without repeating Robin Jackman's masked contact details.
AeroLeads found 1 current-domain work email signal for Robin Jackman. Compare company email patterns before reaching out.
Biopharmaceutical executive with 25 years at the intersection of science, medicine, business, finance:•Successfully led venture-backed orphan drug startup from discovery through successful sale to large pharma in 4 years: novel small molecule discovery platform for treatment of lysosomal storage disorders.•Founded and developed nanoparticle targeting platform from inception to full chemical-biology IP development, preclinical work, manufacturing, clinical candidate, and partnerships with 2 of top 5 pharma.•Headed public company oncology division: advanced immuno-oncology biologic into 125 site worldwide phase III pivotal trial with clinical development, legal, regulatory, and multiple commercialization partnerships.•Led preclinical critical care company from concept-stage through new IP, full CMC development, IND filings and into Phase 2 efficacy clinical trials.Expert in biopharma strategy, finance, partnerships, and building new programs from discovery through clinical development. Career completion of $11.5 billion in deal value through 90+ biopharma transactions covering all aspects of partnership, finance, and M&A. Graduate degrees from Harvard Medical School and Harvard University, undergraduate Stanford University.Specialties: drug and platform development, clinical development, business development, biopharmaceutical partnerships, capital raising
Listed skills include Biotechnology, Drug Development, Clinical Development, Pharmaceutical Industry, and 25 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
San Diego, California, US
Chemically Targeted Mutant-selective Protein Degradation. Venquis Therapeutics has a platform to discover and develop mechanistically differentiated targeted small molecule direct protein degraders. Initial compounds target clinically relevant proteins in a mutant-selective fashion: degrading the driver-mutant proteins while sparing their corresponding.
Biopharmaceutical management, clinical, partnership, and strategy consulting services
San Diego, California, US
January Therapeutics is developing next generation targeted anti-cancer therapy. Building upon the finding that albumin-based nano-formulations have led to substantial improvements in the efficacy of known drugs, January develops unique chemical matter to leverage well established anti-cancer mechanisms of action while adding new cancer targeting.
Led preclinical biopharma company from concept-stage in critical care medicine through full CMC development, new IP, IND filings, capital raising, and into Phase 2 efficacy clinical trial. LBS develops small molecule therapies to treat critical illness from ischemia/GI breakdown: specifically surgically-induced cardiogenic shock and preventing abdominal.
Hands-on direction of all aspects of company development in fast-moving startup - first in class / first in disease NCEs across 4 programs with novel biomarker platform. Small molecule-enabled entry into treatment of new orphan disease indications. Multiple therapeutic and biomarker collaborations established. Sold to BioMarin Pharmaceuticals in 2013.
San Diego, CA, US
Re-built and ran oncology business unit - entered company's lead drug into worldwide Phase 3 pivotal trial.
San Diego, CA, US
Head of business development. Negotiating and executing external alliances, included first collaboration for an internally-developed drug
Westborough, Massachusetts, US
Strategic initiatives and M&A, business development, buy-side & sell-side wall street management
Charlotte, NC, US
All aspects of strategic advisory and corporate finance for biotechnology and biopharmaceutical companies in the public and private markets. Completed transaction value over $10 billion.
Quick answers generated from the profile data available on this page.
Robin Jackman works for Venquis Therapeutics.
Robin Jackman is listed as Founder and CEO, Venquis Therapeutics at Venquis Therapeutics.
AeroLeads has found 1 work email signal at @januarytx.com for Robin Jackman at Venquis Therapeutics.
AeroLeads has found 2 phone signal(s) with area code 858 for Robin Jackman at Venquis Therapeutics.
Robin Jackman is based in San Diego, California, United States while working with Venquis Therapeutics.
Robin Jackman has worked for Venquis Therapeutics, Blue Tungsten Llc, January Therapeutics, Leading Biosciences, and Zacharon Pharmaceuticals (Now Biomarin).
You can use AeroLeads to view verified contact signals for Robin Jackman at Venquis Therapeutics, including work email, phone, and LinkedIn data when available.
Robin Jackman holds Ph.D., Immunology from Harvard University.
Robin Jackman is listed with skills including Biotechnology, Drug Development, Clinical Development, Pharmaceutical Industry, Life Sciences, Biopharmaceuticals, Lifesciences, and Business Development.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts